Neurourology and Urodynamics · 1997 · 43 citations · 0 references
MedicinePharmacotherapyUrologyBladder ManagementClinical PharmacologyFemale UrologyBladder DysfunctionDetrusor OveractivityIncontinence ManagementUrge Urinary IncontinenceUrinary ContinenceUrinary IncontinenceDetrusor Overactivity ManagementLower Urinary Tract Symptom ManagementPad WeighingPharmacologic Bladder ManagementPharmacologic Treatment Of IncontinenceUrge Incontinence ManagementUrinary Symptom Assessment
Oxybutynin has long been used for the treatment of patients with detrusor overactivity and urinary urge incontinence. The short half-life of oxybutynin administered as a conventional tablet formulation or syrup requires 2-3 times daily dosage to be effective. A new controlled release (CR) tablet for once-daily administration has been developed. The efficacy and tolerability of this new controlled release tablet was compared to that of a 5-mg conventional oxybutynin tablet administered twice daily. Seventeen female incontinent patients were studied in a double-dummy crossover trial. Efficacy and tolerability were assessed by using a voiding diary, pad-weighing test, visual-analogue scale (VAS), and questionnaire. Adverse events were recorded spontaneously on a questionnaire by the patients themselves throughout the study. Serum concentrations of oxybutynin and its active metabolite N-desethyloxybutynin were studied after both a single dose and multiple dosage. There was no difference in efficacy between the two formulations. Depending on the parameters tested, the change from baseline values in a positive direction ranged from 15 to 53%. The incidence of adverse events was similar with both formulations. Oxybutynin or its metabolite showed no cumulation during the multiple dosage with a 10-mg CR tablet. The controlled release tablet formulation is as effective and as well-tolerated as the conventional one, but has the advantage of only once-a-day dosage, enhancing treatment compliance.